Current partner codePEPTIDESDE
NCT00765882·Phase 3·INTERVENTIONAL

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Status

Completed

Phase

Phase 3

Enrollment

633

Locations

108

Results

Posted

Publications

2

Study summary

What the protocol is testing.

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder

Interventions

Treatment arms and agents.

DRUG

Linaclotide 290 micrograms

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

DRUG

Linaclotide 145 micrograms

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

DRUG

Placebo

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Timeline

From registration to results.

  1. First posted

    Oct 3, 2008

  2. Study start

    Sep 2008

  3. Primary completion

    Jul 2009

  4. Study completion

    Aug 2009

  5. Results posted

    Jan 30, 2013

  6. Registry updated

    Jan 30, 2013

Outcomes

What the study measures.

Primary outcomes

Complete Spontaneous Bowel Movement (CSBM) Overall Responder

Time frame · Change from Baseline to Week 12

A 12-week CSBM overall responders was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline. A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation. An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Secondary outcomes

12-week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate

Time frame · Change from Baseline to Week 12

The number of CSBMs per week.

12-Week Spontaneous Bowel Movement (SBM) Frequency Rate

Time frame · Change from Baseline to Week 12

A patient's 12-week spontaneous bowel movement (SBM) frequency rate was the number of SBMs per week calculated over the 12-weeks of the treatment period.

12-Week Stool Consistency

Time frame · Change from Baseline to Week 12

The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale: 1. = separate hard lumps like nuts \[difficult to pass\] 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges \[passed easily\] 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces \[entirely liquid\]

12-Week Severity of Straining

Time frame · Change from Baseline to Week 12

Straining is measured on a 5-point scale, where a value of 1 is "not at all" and a value of 5 is "an extreme amount.

12-Week Abdominal Discomfort

Time frame · Change from Baseline to Week 12

Abdominal discomfort is based on a 5-point scale where a value of l is "none" and a value of 5 is "very severe."

12-Week Bloating

Time frame · Change from Baseline to Week 12

Bloating was based on a 5-point scale where a value of l is "none" and a value of 5 is "very severe".

12-Week Constipation Severity

Time frame · Change from Baseline to Week 12

Constipation severity was based on a 5-point ordinal scale where a value of l is "none" and a value of 5 is "very severe".

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings * Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests * Patient meets protocol criteria for CC: reports \< 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs * Patient demonstrates continued chronic constipation through Pretreatment Period * Patient is compliant with IVRS Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS) * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

Study locations

108 registered sites.

Canada · United States. Showing up to 24 locations stored in the fast local snapshot.

Forest Investigative Site

Birmingham, Alabama, United States

Forest Investigative Site

Birmingham, Alabama, United States

Forest Investigative Site

Huntsville, Alabama, United States

Forest Investigative Site

Chandler, Arizona, United States

Forest Investigative Site

Mesa, Arizona, United States

Forest Investigative Site

Peoria, Arizona, United States

Forest Investigative Site

Phoenix, Arizona, United States

Forest Investigative Site

Scottsdale, Arizona, United States

Forest Investigative Site

Tucson, Arizona, United States

Forest Investigative Site

Burbank, California, United States

Forest Investigative Site

Encinitas, California, United States

Forest Investigative Site

Foothill Ranch, California, United States

Forest Investigative Site

Los Angeles, California, United States

Forest Investigative Site

Orange, California, United States

Forest Investigative Site

Westlake Village, California, United States

Forest Investigative Site

Boulder, Colorado, United States

Forest Investigative Site

Colorado Springs, Colorado, United States

Forest Investigative Sites

Denver, Colorado, United States

Forest Investigative Site

Longmont, Colorado, United States

Forest Investigative Site

Wheat Ridge, Colorado, United States

Forest Investigative Site

Waterbury, Connecticut, United States

Forest Investigative Site

Boca Raton, Florida, United States

Forest Investigative Site

Bradenton, Florida, United States

Forest Investigative Site

Brooksville, Florida, United States

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.